Polymorphisms of Oxidation at Carbon Centers of Drugs and Their Clinical Significance
- 1 January 1979
- journal article
- review article
- Published by Taylor & Francis in Drug Metabolism Reviews
- Vol. 9 (2) , 301-317
- https://doi.org/10.3109/03602537908993896
Abstract
No abstract availableThis publication has 11 references indexed in Scilit:
- Hypotensive response to debrisoquine and hydroxylation phenotypeLife Sciences, 1978
- Clinical consequences of polymorphic acetylation of basic drugsClinical Pharmacology & Therapeutics, 1977
- Disease and Acetylation PolymorphismClinical Pharmacokinetics, 1977
- Metabolism of Debrisoquine Sulphate in Rat, Dog and ManXenobiotica, 1976
- The Metabolism and Excretion of Guanoxan in ManXenobiotica, 1972
- BIOCHEMICAL AND GENETIC FACTORS REGULATING DILANTIN METABOLISM IN MAN*Annals of the New York Academy of Sciences, 1971
- ACETOPHENETIDIN-INDUCED METHEMOGLOBINEMIAAnnals of the New York Academy of Sciences, 1968
- Treatment of Data from Drug Urinary ExcretionNature, 1967
- Clinical observations on the effects of debrisoquine sulphate in patients with high blood-pressure.BMJ, 1966
- Studies on debrisoquine sulphate.BMJ, 1966